"""
Question: 1101

Evidence: This cross-sectional study utilized 128 HIV-positive plasma samples obtained from patients enrolled for routine viral monitoring in Nairobi clinics between 2015 and 2017. The authors are deeply grateful to the study subjects who participated in this study.

Rationale: The paper describes a specific, original cross-sectional study conducted by the authors using 128 plasma samples collected between 2015 and 2017. The acknowledgment section thanks the study subjects for their participation, confirming this is original research reporting new, previously unpublished data collected by the authors.

Answer: Yes
"""

"""
Question: 1102

Evidence: The polymerase ( *pol)* gene sequencing was performed using Thermo Fisher Scientific ^TM^ HIV Genotyping kit. The *pol* sequences were achieved in the EMBL Nucleotide Database with the following accession numbers, [MW165068-MW165069, MW178208-MW178236, and MW995389-MW995470].

Rationale: The methods section explicitly describes sequencing the HIV polymerase (pol) gene and provides specific EMBL Nucleotide Database accession numbers for the obtained sequences, confirming that HIV sequences were generated and reported in this study.

Answer: Yes
"""

"""
Question: 1103

Evidence: This was a cross-sectional study that utilized 128 plasma samples from HIV-1 infected and treatment-experienced people with virological failure who lived in Nairobi - Kenya , between August 2015 and August 2017.

Rationale: The paper describes a clinical study using patient-derived plasma samples. There is no mention of in vitro passage experiments anywhere in the text. The study design is explicitly cross-sectional using clinical samples from HIV-infected individuals.

Answer: No
"""

"""
Question: 1104

Evidence: HIV-1 drug resistance mutations were found in 82.3% of the subjects, with 15.3% of subjects having triple-class ART resistance and 45.2% having dual-class resistance. drug resistance mutations identified using Stanford human immunodeficiency virus database genotyping algorithm.

Rationale: The paper reports genotypic drug resistance data identified through sequencing and interpretation using the Stanford HIV Drug Resistance Database. There is no mention of in vitro antiretroviral susceptibility testing or phenotypic assays measuring drug susceptibility in cell culture.

Answer: No
"""

"""
Question: 2101

Evidence: The *pol* sequences were achieved in the EMBL Nucleotide Database with the following accession numbers, [MW165068-MW165069, MW178208-MW178236, and MW995389-MW995470].

Rationale: The paper explicitly states that the sequenced HIV isolates were deposited in the EMBL Nucleotide Database and provides specific GenBank accession numbers for these sequences, confirming that GenBank accession numbers for sequenced HIV isolates are reported.

Answer: Yes
"""

"""
Question: 2102

Evidence: This was a cross-sectional study that utilized 128 plasma samples from HIV-1 infected and treatment-experienced people with virological failure who lived in Nairobi - Kenya , between August 2015 and August 2017. The *pol* sequences were achieved in the EMBL Nucleotide Database with the following accession numbers, [MW165068-MW165069, MW178208-MW178236, and MW995389-MW995470].

Rationale: The study used clinical samples from treatment-experienced patients in Kenya, not laboratory HIV isolates. The provided GenBank accession numbers are for these clinical isolates, confirming the paper reports GenBank accession numbers for sequenced HIV isolates other than those for laboratory HIV isolates.

Answer: Yes
"""

"""
Question: 2103

Evidence: The *pol* sequences were achieved in the EMBL Nucleotide Database with the following accession numbers, [MW165068-MW165069, MW178208-MW178236, and MW995389-MW995470].

Rationale: The paper explicitly lists the GenBank accession numbers for the sequenced HIV isolates in the methods section, providing the specific range of accession numbers assigned to the sequences generated in this study.

Answer: MW165068-MW165069, MW178208-MW178236, MW995389-MW995470
"""

"""
Question: 2202

Evidence: M184 V/I 87 (28.8%), K65R/E/N 27 (8.9%), L74 V 3 (1.0%), and Y115F 12 (4.0%) were the mutations conferring resistance to NRTIs. K103N/S 56 (21.0%), G190S/A 39 (14.6%), Y181C/I 29 (10.9%), V108I 13 (4.9%), P225H 12 (4.5%), Y188L 7 (2.6%), M230L 7 (2.6%), L100I 5 (1.9%), V106 M 5 (1.9%), and K101P 2 (0.7%) were the mutations conferring resistance to NNRTIs.

Rationale: The results section provides detailed lists of mutations found in the study population, including specific mutation names and their frequencies among subjects. However, the paper reports aggregate mutation frequencies across the cohort rather than providing lists of mutations for individual sequenced HIV isolates.

Answer: No
"""

"""
Question: 2301

Evidence: HIV-1 drug resistance mutations were found in 82.3% of the subjects. The study population consisted of HIV-infected individuals visiting Nairobi HIV clinics for routine care.

Rationale: Throughout the paper, the virus is consistently referred to as "HIV-1" (human immunodeficiency virus type 1). There is no mention of HIV-2 or other HIV species in the study.

Answer: HIV-1
"""

"""
Question: 2302

Evidence: HIV-1 subtypes were found to have a wide range of distribution. HIV-Subtype A accounted for 63.3% of all subtypes while subtype D accounted for 13.3% and CRF01_AE 10.2%. A2, B, G, J, and K accounted for 6.2% of the total.

Rationale: The results section provides detailed information about the distribution of HIV subtypes among the sequenced viruses, listing the specific subtypes identified and their respective percentages in the study population.

Answer: A, D, CRF01_AE, C, A2, B, G, J, K
"""

"""
Question: 2303

Evidence: The polymerase ( *pol)* gene sequencing was performed using Thermo Fisher Scientific ^TM^ HIV Genotyping kit. that amplifies a 1.1-kb fragment including protease (6--99) and reverse transcriptase (1--251) regions was performed as per manufacturer's instructions.

Rationale: The methods section explicitly describes which HIV genes were sequenced, specifying that the polymerase (pol) gene was sequenced, which includes both the protease and reverse transcriptase regions of the HIV genome.

Answer: pol gene (including protease and reverse transcriptase regions)
"""

"""
Question: 2304

Evidence: The primary outcome was human immunodeficiency virus type 1 (HIV-1) drug resistance mutation counts determined by Sanger sequencing of the polymerase (pol) gene. The polymerase ( *pol)* gene sequencing was performed using Thermo Fisher Scientific ^TM^ HIV Genotyping kit.

Rationale: The paper explicitly states that HIV pol gene sequencing was performed as the primary method for detecting drug resistance mutations, confirming that the results of HIV pol sequences are reported.

Answer: Yes
"""

"""
Question: 2401

Evidence: This was a cross-sectional study that utilized 128 plasma samples from HIV-1 infected and treatment-experienced people with virological failure who lived in Nairobi - Kenya. The prevalence of HIV-1 infection among adults (15--49 years) in Nairobi is 8.4%.

Rationale: The paper clearly states that the study was conducted in Nairobi, Kenya, and that all participants resided in Nairobi County during the enrollment period, confirming the geographic origin of the sequences.

Answer: Nairobi, Kenya
"""

"""
Question: 2402

Evidence: This cross-sectional study utilized 128 HIV-positive plasma samples obtained from patients enrolled for routine viral monitoring in Nairobi clinics between 2015 and 2017. between August 2015 and August 2017.

Rationale: The paper explicitly states the time period during which samples were obtained for the study, specifying that samples were collected between 2015 and 2017, with the enrollment period being August 2015 to August 2017.

Answer: 2015-2017
"""

"""
Question: 2502

Evidence: The primary outcome was human immunodeficiency virus type 1 (HIV-1) drug resistance mutation counts determined by Sanger sequencing of the polymerase (pol) gene. Sanger sequencing was performed using BigDye XTerminator kit on Applied Biosystems 3500xL DX genetic analyzer.

Rationale: The methods section explicitly states that Sanger sequencing was used for HIV genotyping and provides details about the specific Sanger sequencing platform and reagents used.

Answer: Yes
"""

"""
Question: 2503

Evidence: Sanger sequencing was performed using BigDye XTerminator kit on Applied Biosystems 3500xL DX genetic analyzer.

Rationale: The paper explicitly describes using Sanger sequencing technology and does not mention any next-generation sequencing (NGS) technologies. The described methodology and equipment are characteristic of traditional Sanger sequencing.

Answer: No
"""

"""
Question: 2504

Evidence: HIV-1 RNA extraction was carried out using the Abbott M2000SP automated platform. 10 μL of extracted RNA was incubated at 65°C for 10 minutes and mixed with 40 μL Reverse Transcription-Polymerase Chain Reaction Master Mix.

Rationale: The methods describe direct amplification from viral RNA without any mention of cloning procedures. The workflow involves RNA extraction, reverse transcription, PCR amplification, and direct sequencing without cloning steps.

Answer: No
"""

"""
Question: 2505

Evidence: For nested PCR, 2 μL of PCR products were amplified in a 50 μL reaction with AmpliTaq Gold LD DNA polymerase. The amplified PCR fragment was purified using Clean Sweep PCR purification reagent.

Rationale: The paper describes standard bulk PCR amplification methods rather than single genome sequencing. There is no mention of limiting dilution or other techniques used for single genome sequencing.

Answer: No
"""

"""
Question: 2506

Evidence: HIV-1 RNA extraction was carried out using the Abbott M2000SP automated platform. The polymerase gene amplification and sequencing was performed using Thermo Fisher Scientific HIV Genotyping workflow.

Rationale: The methods describe direct amplification and sequencing from plasma viral RNA without any mention of molecular cloning procedures. The workflow involves standard PCR amplification followed by direct sequencing.

Answer: No
"""

"""
Question: 2601

Evidence: HIV-1 RNA extraction was carried out using the Abbott M2000SP automated platform in accordance with the manufacturer's instructions. Briefly 350 μL of plasma was lysed using 4.7 M guanidium isothiocyanate and 10% tween.

Rationale: The methods section explicitly describes plasma virus sequencing, detailing the RNA extraction process from plasma samples and subsequent sequencing of the viral RNA.

Answer: Yes
"""

"""
Question: 2602

Evidence: HIV-1 RNA extraction was carried out using the Abbott M2000SP automated platform. Briefly 350 μL of plasma was lysed using 4.7 M guanidium isothiocyanate and 10% tween.

Rationale: The paper only describes sequencing from plasma viral RNA. There is no mention of PBMC isolation, DNA extraction, or proviral DNA sequencing anywhere in the text.

Answer: No
"""

"""
Question: 2603

Evidence: This cross-sectional study utilized 128 HIV-positive plasma samples obtained from patients enrolled for routine viral monitoring in Nairobi clinics between 2015 and 2017.

Rationale: The paper explicitly states that 128 plasma samples were utilized in the study, and the methods describe sequencing being performed on RNA extracted from these plasma samples, confirming that 128 samples underwent plasma virus sequencing.

Answer: 128
"""

"""
Question: 2604

Evidence: HIV-1 RNA extraction was carried out using the Abbott M2000SP automated platform. Briefly 350 μL of plasma was lysed using 4.7 M guanidium isothiocyanate and 10% tween.

Rationale: The paper only describes sequencing from plasma viral RNA and does not mention PBMC virus sequencing at any point. All sequencing was performed on plasma-derived viral RNA.

Answer: 0
"""

"""
Question: 2605

Evidence: Individuals who met the following criteria were included into the study: being diagnosed with virologic failure (Viral load >1000 copies/mL) despite being on ART.

Rationale: The inclusion criteria specify that all participants had virological failure with viral load >1000 copies/mL, indicating active HIV replication at the time of sampling.

Answer: Yes
"""

"""
Question: 2606

Evidence: HIV-1 RNA extraction was carried out using the Abbott M2000SP automated platform. Briefly 350 μL of plasma was lysed using 4.7 M guanidium isothiocyanate and 10% tween.

Rationale: The paper explicitly describes sequencing from plasma viral RNA, not from proviral DNA. There is no mention of PBMC DNA extraction or proviral DNA sequencing in the methods or results sections.

Answer: No
"""

"""
Question: 2701

Evidence: The study population consisted of HIV-infected individuals visiting Nairobi HIV clinics for routine care. Individuals who met the following criteria were included into the study: 15 years old.

Rationale: The inclusion criteria specify that participants were 15 years or older, and the age stratification in Table 1 shows the youngest age group as 15-25 years. There is no mention of infants or children under 15 years old.

Answer: No
"""

"""
Question: 2702

Evidence: This was a cross-sectional study that utilized 128 plasma samples from HIV-1 infected and treatment-experienced people with virological failure who lived in Nairobi - Kenya , between August 2015 and August 2017.

Rationale: The paper describes a cross-sectional observational study using samples from patients enrolled for routine viral monitoring in clinical care settings. There is no mention of a clinical trial, intervention study, or randomized controlled trial.

Answer: No
"""

"""
Question: 2703

Evidence: This was a cross-sectional study that utilized 128 plasma samples from HIV-1 infected and treatment-experienced people with virological failure who lived in Nairobi - Kenya , between August 2015 and August 2017.

Rationale: The study design is explicitly described as a cross-sectional observational study using routine clinical care samples. There is no indication that any participants were involved in a clinical trial.

Answer: No
"""

"""
Question: 3101

Evidence: This cross-sectional study utilized 128 HIV-positive plasma samples obtained from patients enrolled for routine viral monitoring in Nairobi clinics between 2015 and 2017.

Rationale: The paper explicitly states that 128 plasma samples were utilized in the study, and since each sample came from an individual patient, this represents the total number of individuals who had samples obtained for HIV sequencing.

Answer: 128
"""

"""
Question: 3102

Evidence: This cross-sectional study utilized 128 HIV-positive plasma samples obtained from patients enrolled for routine viral monitoring in Nairobi clinics between 2015 and 2017.

Rationale: The paper describes using all 128 plasma samples for HIV sequencing, as evidenced by the methods section detailing the sequencing workflow applied to these samples. All individuals included in the study underwent HIV sequencing.

Answer: Yes
"""

"""
Question: 4101

Evidence: The study population consisted of HIV-infected individuals visiting Nairobi HIV clinics for routine care. Individuals who met the following criteria were included into the study: receiving ART for at least 6 months.

Rationale: The inclusion criteria explicitly require participants to be receiving ART for at least 6 months, indicating all individuals were treatment-experienced. There is no mention of ART-naive individuals in the study population.

Answer: No
"""

"""
Question: 4102

Evidence: This was a cross-sectional study that utilized 128 plasma samples from HIV-1 infected and treatment-experienced people with virological failure. Individuals who met the following criteria were included into the study: receiving ART for at least 6 months.

Rationale: The paper explicitly describes the study population as "treatment-experienced" and the inclusion criteria require participants to have been receiving ART for at least 6 months, confirming that all individuals had previously received ARV drugs.

Answer: Yes
"""

"""
Question: 4103

Evidence: This was a cross-sectional study that utilized 128 plasma samples from HIV-1 infected and treatment-experienced people with virological failure. receiving ART for at least 6 months.

Rationale: The study population is explicitly described as consisting only of treatment-experienced individuals who had been on ART for at least 6 months. There is no mention of ART-naive individuals being included in the study.

Answer: No
"""

"""
Question: 4104

Evidence: This was a cross-sectional study that utilized 128 plasma samples from HIV-1 infected and treatment-experienced people with virological failure. receiving ART for at least 6 months.

Rationale: The inclusion criteria explicitly state that all participants were receiving ART for at least 6 months, indicating no ART-naive individuals were included in the study.

Answer: 0
"""

"""
Question: 4105

Evidence: Clinical data (viral load, treatment-duration, and ART-regimen) were obtained from medical records. TDF+3TC+EFV (50.4%), AZT+3TC+NVP (22.0%), and TDF+3TC+NVP (10.2%) were the 3 most commonly prescribed ART-regimens.

Rationale: While the paper reports current ART regimens and treatment duration, it does not claim to have complete ART history information for all individuals. The focus is on current regimens rather than comprehensive historical treatment data.

Answer: No
"""

"""
Question: 4201

Evidence: This was a cross-sectional study that utilized 128 plasma samples from HIV-1 infected and treatment-experienced people with virological failure. receiving ART for at least 6 months.

Rationale: The study population consists entirely of treatment-experienced individuals with virological failure, which represents acquired drug resistance rather than transmitted drug resistance. There is no mention of studying transmission networks or newly diagnosed individuals.

Answer: No
"""

"""
Question: 4202

Evidence: This was a cross-sectional study that utilized 128 plasma samples from HIV-1 infected and treatment-experienced people with virological failure. receiving ART for at least 6 months.

Rationale: The study focuses on individuals who were already on ART and experiencing virological failure, representing acquired drug resistance. Pretreatment HIV drug resistance typically refers to resistance in ART-naive individuals or those starting treatment, which is not the population studied here.

Answer: No
"""

"""
Question: 4301

Evidence: TDF+3TC+EFV (50.4%), AZT+3TC+NVP (22.0%), and TDF+3TC+NVP (10.2%) were the 3 most commonly prescribed ART-regimens. Overall, NVP 132 (81.0%), EFV 116 (71.2%), 3TC 108 (66.3%), and FTC 108 (66.3%) were found to have disproportionately high levels of resistance.

Rationale: The paper reports that individuals received regimens containing NRTIs (TDF, AZT, 3TC, ABC, FTC) and NNRTIs (EFV, NVP), and some received PIs (ATV/r, LPV/r). The"""
Question: 4302

Evidence: The current first-line ART for adults is tenofovir disoproxil fumarate (TDF) + lamivudine (3TC) + dolutegravir (DTG) or TDF+3TC+ efavirenz (EFV). Patients with virological failure on zidovudine (AZT), lopinavir/ritonavir, nevirapine (NVP), and EFV are to be switched to DTG.

Rationale: While the paper mentions DTG as part of current Kenyan guidelines and as a switch option for failing regimens, the results section describing the actual ART regimens used by study participants does not list any integrase inhibitor-containing regimens. The reported regimens consist of NRTIs + NNRTIs or NRTIs + PIs.

Answer: No
"""

"""
Question: 4303

Evidence: AZT+3TC+ATV/r, TDF+3TC+ATV/r, or DTG- based 2nd line ART) based on viral load results. AZT+3TC+ATV/r, ABC+3TC+LPV/r, AZT+3TC+LPV/r, TDF+3TC+ATV/r.

Rationale: The paper reports that some individuals received protease inhibitor-containing regimens, specifically listing ATV/r (atazanavir/ritonavir) and LPV/r (lopinavir/ritonavir) in both the background information and the results tables.

Answer: Yes
"""

"""
Question: 4304

Evidence: TDF+3TC+EFV (50.4%), AZT+3TC+NVP (22.0%), and TDF+3TC+NVP (10.2%) were the 3 most commonly prescribed ART-regimens. There was no significant difference in the prescription of ART-regimens between males and females, P = .093.

Rationale: The results show that multiple different ART regimens were prescribed to study participants, with TDF+3TC+EFV being the most common at 50.4%, followed by AZT+3TC+NVP at 22.0%, and other regimens comprising the remainder.

Answer: No
"""

"""
Question: 4305

Evidence: TDF+3TC+EFV (50.4%), AZT+3TC+NVP (22.0%), and TDF+3TC+NVP (10.2%) were the 3 most commonly prescribed ART-regimens.

Rationale: The reported ART regimens for study participants consist of NRTI + NNRTI combinations or NRTI + PI combinations. There is no mention of any integrase strand transfer inhibitor (INSTI)-containing regimens being used by the study participants.

Answer: Yes
"""

"""
Question: 4403

Evidence: Clinical data (viral load, treatment-duration, and ART-regimen) were obtained from medical records. TDF+3TC+EFV (50.4%), AZT+3TC+NVP (22.0%), and TDF+3TC+NVP (10.2%) were the 3 most commonly prescribed ART-regimens.

Rationale: The paper only reports the current ART regimens at the time of sampling. There is no information provided about previous ART regimens or whether individuals had received more than one ART regimen over their treatment history.

Answer: NA
"""

"""
Question: 4404

Evidence: Clinical data (viral load, treatment-duration, and ART-regimen) were obtained from medical records. TDF+3TC+EFV (50.4%), AZT+3TC+NVP (22.0%), and TDF+3TC+NVP (10.2%) were the 3 most commonly prescribed ART-regimens.

Rationale: The paper provides information only about current ART regimens and does not include historical treatment data that would indicate whether individuals had received more than two ART regimens during their treatment history.

Answer: NA
"""

"""
Question: 4405

Evidence: TDF+3TC+EFV (50.4%), AZT+3TC+NVP (22.0%), and TDF+3TC+NVP (10.2%) were the 3 most commonly prescribed ART-regimens. There was no significant difference in the prescription of ART-regimens between males and females, P = .093.

Rationale: The results show that multiple different ART regimens were prescribed to study participants, indicating that not all individuals received the same number of ART regimens, though the paper does not explicitly address the number of regimens received by each individual.

Answer: No
"""

"""
Question: 4406

Evidence: TDF+3TC+EFV (50.4%), AZT+3TC+NVP (22.0%), and TDF+3TC+NVP (10.2%) were the 3 most commonly prescribed ART-regimens.

Rationale: While the paper reports current ART regimens, it does not provide information about whether these represent the first, second, or subsequent regimens for each individual. The data presented only reflects the regimen at the time of sampling, not the total number of regimens received.

Answer: NA
"""

"""
Question: 4501

Evidence: TDF+3TC+EFV (50.4%), AZT+3TC+NVP (22.0%), and TDF+3TC+NVP (10.2%) were the 3 most commonly prescribed ART-regimens.

Rationale: The reported ART regimens for study participants do not include dolutegravir (DTG). While DTG is mentioned in the introduction as part of current Kenyan guidelines, the results show that study participants were on older regimens containing EFV or NVP rather than DTG.

Answer: 0
"""

"""
Question: 4502

Evidence: There were no other mutations at L76 V, I47 V, I50 V, I54 M/L, or I84 V. Lopinavir was the only PI class that demonstrated significant HIVDRM with mutations at V32I (2 patients), I47 V/A (2 patients), and V82A/F/T/S (3 patients). This study found no atazanavir resistance mutations (I50L, I84 V, or N88S).

Rationale: The paper mentions darunavir only in the context of resistance mutations (M46I confers Darunavir resistance), but there is no information about whether any individuals actually received darunavir as part of their treatment regimen. The reported PI regimens are ATV/r and LPV/r.

Answer: NA
"""

"""
Question: 5101

Evidence: HIV-1 drug resistance mutations were found in 82.3% of the subjects. The median HIVDRM per subject was 5 (IQR, 1.75--7).

Rationale: The paper explicitly states that 82.3% of subjects had HIV drug resistance mutations, and the median number of mutations per subject was 5. This indicates that 82.3% of individuals had one or more drug resistance mutation.

Answer: 105 (82.3% of 128 subjects)
"""

"""
Question: 5102

Evidence: HIV-1 drug resistance mutations were found in 82.3% of the subjects, with 15.3% of subjects having triple-class ART resistance and 45.2% having dual-class resistance.

Rationale: The paper reports resistance to NRTIs, NNRTIs, and PIs, but does not mention any integrase strand transfer inhibitor (INSTI) resistance mutations. The study sequenced the pol gene which includes protease and reverse transcriptase but not integrase.

Answer: 0
"""

"""
Question: 5103

Evidence: K65R/E/N mutations conferred resistance to TDF and were found in 8.9% of subjects. K65R/E/N 27 (8.9%).

Rationale: The paper explicitly states that K65R/E/N mutations confer resistance to TDF (tenofovir disoproxil fumarate) and reports that these mutations were found in 27 subjects, which represents 8.9% of the study population.

Answer: 27
"""

"""
Question: 5104

Evidence: HIV-1 drug resistance mutations were found in 82.3% of the subjects, with 15.3% of subjects having triple-class ART resistance and 45.2% having dual-class resistance.

Rationale: The paper does not report any INSTI-resistance mutations. The study sequenced only the pol gene (protease and reverse transcriptase regions) and did not sequence the integrase region where INSTI-resistance mutations would be found.

Answer: None reported
"""

"""
Question: 6101

Evidence: drug resistance mutations identified using Stanford human immunodeficiency virus database genotyping algorithm.

Rationale: The paper used genotypic drug resistance testing through sequencing and interpretation using the Stanford HIV Drug Resistance Database. There is no mention of phenotypic susceptibility testing being performed in the study.

Answer: No phenotypic susceptibility test was used
"""

"""
Question: 6102

Evidence: drug resistance mutations identified using Stanford human immunodeficiency virus database genotyping algorithm. HIVDRM counts were the primary outcome of concern.

Rationale: The study used genotypic resistance testing only, measuring mutation counts as the primary outcome. There is no mention of IC50, IC90, or any other inhibitory concentration values that are characteristic of phenotypic susceptibility testing.

Answer: No
"""

"""
Question: 6103

Evidence: drug resistance mutations identified using Stanford human immunodeficiency virus database genotyping algorithm. Poisson regression was used to determine the effects of sex, viral load, age, HIV-subtype, treatment duration, and ART-regimen on the primary outcome.

Rationale: The paper reports genotypic resistance data and statistical analysis of mutation counts, but does not mention IC50 fold change values or any other phenotypic susceptibility measures.

Answer: No
"""

"""
Question: 6104

Evidence: drug resistance mutations identified using Stanford human immunodeficiency virus database genotyping algorithm.

Rationale: The paper used genotypic drug resistance testing through sequencing and interpretation algorithms. There is no mention of any phenotypic susceptibility assay being used in the study.

Answer: No phenotypic susceptibility assay was used
"""

"""
Question: 6105

Evidence: HIV-1 drug resistance mutation counts determined by Sanger sequencing of the polymerase (pol) gene followed by interpretation using Stanford's HIV Drug Resistance Database.

Rationale: The study focused on genotypic drug resistance testing and did not measure or report any data about viral replication capacity.

Answer: No
"""

"""
Question: 6106

Evidence: drug resistance mutations identified using Stanford human immunodeficiency virus database genotyping algorithm.

Rationale: The paper used genotypic resistance testing rather than phenotypic susceptibility testing. Therefore, no drugs were tested using phenotypic susceptibility assays.

Answer: No drugs were tested using phenotypic susceptibility assays
"""

"""
Question: 7101

Evidence: This was a cross-sectional study that utilized 128 plasma samples from HIV-1 infected and treatment-experienced people with virological failure who lived in Nairobi - Kenya.

Rationale: The study used clinical samples from treatment-experienced patients with virological failure. There is no mention of site-directed mutagenesis or engineered viral isolates anywhere in the paper.

Answer: No
"""

"""
Question: 7102

Evidence: This was a cross-sectional study that utilized 128 plasma samples from HIV-1 infected and treatment-experienced people with virological failure who lived in Nairobi - Kenya , between August 2015 and August 2017.

Rationale: The paper describes a clinical study using patient-derived plasma samples. There is no mention of in vitro passage experiments or viruses generated through laboratory passage studies.

Answer: No
"""